ArticleNPJ breast cancer2025
Quantitative analysis of T cell subsets in a population of Black women with invasive breast cancer.
Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
We compared T cell subpopulations in primary invasive breast tumors from Black and White women and investigated breast cancer subtype-specific associations of T cell abundance with survival in Black women. Multispectral immune staining was used to quantify helper, cytotoxic, and regulatory T cells in the tumor and stromal compartments of breast tissues. In fully adjusted models, breast tumors from Black women were significantly more likely than those from White women to have a higher abundance of cytotoxic T cells (IRR, 2.41; 95% CI, 1.43-4.05) and helper T cells (IRR, 1.80; 95% CI, 1.06-3.06), and these differences were more pronounced in the tumor than the stromal compartment. Among Black women, higher levels of T cells were associated with improved survival in women with triple-negative breast cancer, whereas a trend of poorer survival was observed in women with HER2-positive tumors. This study contributes to an accumulating body of evidence that the tumor-immune landscape differs between Black and White women.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.